Mesoblast Limited
MESONASDAQHealthcare● Active
$13.80
$-0.15(-1.08%)
Market Cap$1.8B
P/E Ratio—
52W High$21.5
52W Low$9.88
Mesoblast Limited (MESO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MESO · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 26, 2026EPS Actual
-$0.31
Est. -$0.24 · -31.2%
Revenue
$0.05B
Est. $0.05B · -3.3%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 26, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
MESO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.06 | — | — | — | $0.07B | — |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.24 | -$0.31 | -31.2% | $0.05B | $0.05B | -3.3% |
| ◌ Q3 FY2025 | Sep 3, 2025 | -$0.20 | — | — | — | — | — |
| ▲ Q3 FY2025 | Sep 3, 2025 | -$0.37 | -$0.21 | +43.0% | $0.01B | $0.03B | -77.1% |
| — Q2 FY2025 | Apr 30, 2025 | — | -$0.21 | — | $0.01B | $0.01B | -6.2% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.25 | -$0.21 | +16.1% | $0.00B | $0.01B | -78.9% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.31 | -$0.28 | +9.7% | $0.00B | $0.00B | -54.5% |
| ▲ Q3 FY2024 | Jul 4, 2024 | -$0.35 | -$0.26 | +25.7% | — | $0.00B | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.31
EPS Est.
-$0.24
EPS Surpr.
-31.2%
Revenue
$0.05B
Q3 FY2025
Sep 3, 2025
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 3, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.37
EPS Surpr.
+43.0%
Revenue
$0.01B
Q2 FY2025
Apr 30, 2025
EPS Actual
-$0.21
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.25
EPS Surpr.
+16.1%
Revenue
$0.00B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.28
EPS Est.
-$0.31
EPS Surpr.
+9.7%
Revenue
$0.00B
Q3 FY2024
Jul 4, 2024Beat
EPS Actual
-$0.26
EPS Est.
-$0.35
EPS Surpr.
+25.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2031 | $0.62 | $0.62 | $0.62 | 1 |
| Q2 FY2031 | $1.06 | $1.06 | $1.06 | 1 |
| Q1 FY2031 | $0.17 | $0.17 | $0.17 | 1 |
| Q4 FY2030 | $0.08 | $0.08 | $0.08 | 1 |
| Q3 FY2030 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q2 FY2030 | $-0.09 | $-0.09 | $-0.09 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2031 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2031 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2031 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 26, 2026 | -31.2% | $16.91 | $16.92 | +0.06% |
| ▲ Q3 FY2025 | Sep 3, 2025 | +43.0% | $13.12 | $12.88 | -1.83% |
| — Q2 FY2025 | Apr 30, 2025 | — | $11.91 | $11.40 | -4.28% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +16.1% | $16.05 | $15.72 | -2.06% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +9.7% | $9.06 | $8.81 | -2.76% |
| ▲ Q3 FY2024 | Jul 4, 2024 | +25.7% | $6.81 | $7.74 | +13.66% |
| — Q3 FY2024 | Jul 4, 2024 | — | $6.81 | $7.74 | +13.66% |
| ▲ Q1 FY2024 | Mar 25, 2024 | +15.0% | $2.16 | $2.20 | +1.85% |
Q1 FY2026+0.06%
Report Date
Feb 26, 2026
EPS Beat/Miss
-31.2%
Price Before
$16.91
Price After
$16.92
Q3 FY2025-1.83%
Report Date
Sep 3, 2025
EPS Beat/Miss
+43.0%
Price Before
$13.12
Price After
$12.88
Q2 FY2025-4.28%
Report Date
Apr 30, 2025
EPS Beat/Miss
—
Price Before
$11.91
Price After
$11.40
Q1 FY2025-2.06%
Report Date
Feb 26, 2025
EPS Beat/Miss
+16.1%
Price Before
$16.05
Price After
$15.72
Q4 FY2024-2.76%
Report Date
Oct 30, 2024
EPS Beat/Miss
+9.7%
Price Before
$9.06
Price After
$8.81
Q3 FY2024+13.66%
Report Date
Jul 4, 2024
EPS Beat/Miss
+25.7%
Price Before
$6.81
Price After
$7.74
Q3 FY2024+13.66%
Report Date
Jul 4, 2024
EPS Beat/Miss
—
Price Before
$6.81
Price After
$7.74
Q1 FY2024+1.85%
Report Date
Mar 25, 2024
EPS Beat/Miss
+15.0%
Price Before
$2.16
Price After
$2.20
Avg Beat Reaction+1.77%
Avg Miss Reaction+0.06%
Beat Rate5 / 8 quarters
Largest Move+13.66% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MESO ends December
Mesoblast Limited (MESO) most recently reported earnings on February 26, 2026 for Q1 FY2026, posting EPS of $-0.31 — missing the analyst consensus of $-0.24 by -31.2%. The next MESO earnings date is expected around September 1, 2026.
Each quarter, investors track MESO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MESO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MESO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MESO earnings · 5 questionsMesoblast Limited's next earnings report is expected around September 1, 2026. MESO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MESO historically reports after market close (AMC).
MESO earnings datewhen is MESO earningsMESO next earnings datewhen does MESO report earningsMESO earnings calendar
▸ Source: FMP · Mesoblast Limited SEC filings · US GAAP · Mesoblast Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026